Trial Profile
Risk and severity of injection site reactions and flu-like symptoms in patients treated with non-pegylated and pegylated subcutaneous interferon beta drugs
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Feb 2016
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 29 Feb 2016 New trial record
- 10 Oct 2015 Results (n=25) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis